micro

Chirpley Joins NVIDIA Inception

  Chirpley, Amsterdam, March 20th— Chirpley today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements. Chirpley is the world’s first automated peer-to-peer, all-in-one influencer marketplace specifically focused on nano and micro influencers. Chirpley focused on leveraging AI technologies to provide tailored matchmaking for brands and influencers, ensuring efficiency, fair evaluation, and data-driven approach to maximize the reach of marketing incentives. Chirpley plans to use the resources available through NVIDIA Inception, including utilizing NVIDIA most advanced technology assistance and top-notch expertise in AI

Starbox Group’s StarboxAI – ViPro Module: Transforming Content Creation

Kuala Lumpur, Malaysia, Sept 5th, 2023 – Starbox Group Holdings Ltd. (Nasdaq: STBX), a dynamic player in cash rebates, digital advertising, and payment solutions, with a vision of leading in artificial intelligence (“AI”) solutions throughout Southeast Asia, is making waves with the launch of its groundbreaking StarboxAI - ViPro module. This innovative module introduces a text-to-video feature set to redefine content creation. The Text-to-Video feature within the StarboxAI - ViPro module is not just an addition; it's a revelation. It empowers content creators to seamlessly transmute textual instructions or scripts

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating